Hana Biosciences, Inc. - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for Hana Biosciences, Inc.. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

Hana Biosciences, Inc.. The Group's principle activity is to acquire, develop and commercialize of innovative biopharmaceutical products to advance cancer care. It has four product candidates in various stages of development: Marqibo being developed for the treatment of adult acute lymphoblastic leukemia (ALL) and metastatic uveal melanoma. Menadione, a novel supportive care product candidate being developed for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors (EGFRI), a type of anti-cancer agent used in the treatment of certain cancers. Brakiva developed for the treatment of solid tumors including small cell lung cancer and ovarian cancer. Alocrest developed for the treatment of solid tumors such as non-small-cell lung cancer (NSCLC).

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report